Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Research analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Entera Bio in a note issued to investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.28) per share for the year, down from their prior estimate of ($0.23). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Entera Bio's current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Entera Bio's Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.55) EPS.
Entera Bio Stock Up 3.0 %
ENTX stock traded up $0.05 during midday trading on Thursday, hitting $1.72. The company's stock had a trading volume of 2,038,498 shares, compared to its average volume of 125,127. Entera Bio has a 1 year low of $0.52 and a 1 year high of $3.35. The stock has a market cap of $61.55 million, a price-to-earnings ratio of -6.42 and a beta of 1.58. The stock's 50-day moving average price is $1.86 and its 200 day moving average price is $1.92.
Institutional Investors Weigh In On Entera Bio
An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC purchased a new stake in shares of Entera Bio Ltd. (NASDAQ:ENTX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 22,040 shares of the company's stock, valued at approximately $37,000. Institutional investors own 14.11% of the company's stock.
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Featured Stories
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
